SynBiotic SE
XETRA: SBX.DE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Deutsche Börse
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Daniel Kruse
- Employees
- 55
- Headquarters
- Munich, Germany
- IPO year
- 2021
- Market cap
- €9.0M
- Website
- https://www.synbiotic.com
Loading SBX…
Loading profile data…Frequently asked questions about SBX
What does SynBiotic SE (SBX.DE) do?
SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munic...
Where does SBX.DE trade?
SynBiotic SE (SBX.DE) trades on the Deutsche Börse.
What sector is SBX.DE in?
SynBiotic SE (SBX.DE) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of SynBiotic SE?
Daniel Kruse is the chief executive officer of SynBiotic SE (SBX.DE).
Where is SynBiotic SE headquartered?
SynBiotic SE is headquartered in Germany.
Does SBX.DE pay a dividend?
SynBiotic SE (SBX.DE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SBX.DE go public?
SynBiotic SE (SBX.DE) completed its initial public offering in 2021.